메뉴 건너뛰기
Blood
Volumn 106, Issue 12, 2005, Pages 3687-3688
To transplant or not to transplant?
Author keywords

[No Author keywords available]
Indexed keywords

BORTEZOMIB; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;
EID: 28444497047     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3673     Document Type: Review
Times cited : (3)
References (6)
  • 1
    • 8944220233 scopus 로고    scopus 로고
    • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome
    • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
    • (1996) N Engl J Med , vol.335 , pp. 91-97
    • Attal, M.1    Harousseau, J.L.2    Stoppa, A.M.3
  • 2
    • 0037739753 scopus 로고    scopus 로고
    • High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
    • Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
    • (2003) N Engl J Med , vol.348 , pp. 1875-1883
    • Child, J.A.1    Morgan, G.J.2    Davies, F.E.3
  • 3
    • 0032211193 scopus 로고    scopus 로고
    • High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial
    • Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-3136.
    • (1998) Blood , vol.92 , pp. 3131-3136
    • Fermand, J.P.1    Ravaud, P.2    Chevret, S.3
  • 4
    • 2442451992 scopus 로고    scopus 로고
    • Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing mel 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy VBMCP and no benefit from interferon (IFN) maintenance: Results of intergroup trial S9321
    • Barlogie B, Kyle RA, Anderson KC, et al. Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing mel 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy VBMCP and no benefit from interferon (IFN) maintenance: results of intergroup trial S9321 [abstract]. Blood. 2003;102:42a.
    • (2003) Blood , vol.102
    • Barlogie, B.1    Kyle, R.A.2    Anderson, K.C.3
  • 5
    • 8944237979 scopus 로고    scopus 로고
    • Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated
    • Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol. 1996;14:2167-2173.
    • (1996) J Clin Oncol , vol.14 , pp. 2167-2173
    • Blade, J.1    San Miguel, J.F.2    Fontanillas, M.3
  • 6
    • 17944365031 scopus 로고    scopus 로고
    • Nordic Myeloma Study Group: Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
    • Gulbrandsen N, Wisloff F, Brinch L, et al. Nordic Myeloma Study Group: health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol. 2001;18:65-77.
    • (2001) Med Oncol , vol.18 , pp. 65-77
    • Gulbrandsen, N.1    Wisloff, F.2    Brinch, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.